Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 315 participants.
Also called NCT01619059
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 315 participants
- Sponsor
- Registry
-
NCT01619059 -
2011-006323-37
-
- Other papers using this trial's data
- Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Hungary, Mexico, Poland, Puerto Rico, Romania, Russia
- Registry status
- Completed
Technical summary
Registry record NCT01619059. Randomized; triple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2014-06 (actual). Results posted on 2016-03-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Saxagliptin
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Metformin IR
- Intervention (Drug)
- Placebo matching with Saxagliptin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01619059- Content hash
c201179bb3ac98d704887fe77cadaf1511c33ac7f58cf4f23c6e5e873cc4a077